Monique Celeste Tavares

Monique Celeste Tavares

Auto-generated profile, based on publicly available information

Monique Celeste Tavares

A.C. Camargo Cancer Center, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
LLluciana de moura Leite
luciana de moura Leite
MCMarcelle Goldner Cesca
Marcelle Goldner Cesca
MTMonique Celeste Tavares
Monique Celeste Tavares
DSDebora Maciel Santana
Debora Maciel Santana
ESErick F. Saldanha
Erick F. Saldanha
NPNoam Falbel Pondé
Noam Falbel Pondé

5 June 2024 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
DGDebora de Melo Gagliato
Debora de Melo Gagliato
TRTomas Reinert
Tomas Reinert
CRCláudio Rocha
Cláudio Rocha
MTMonique Tavares
Monique Tavares
SPSâmio Pimentel
Sâmio Pimentel
VCVivienne Castilho
Vivienne Castilho
Introduction Biological monoclonal antibodies play a pivotal role in cancer treatment, with biosimilars significantly enhancing their accessibility. In Brazil’s ethnically diverse setting, real-world evidence is crucial for assessing the effectiveness and applicability of these therapies in routine clinical practice. Methods We performed a multicentric, observational, prospective real-world study on biosimilar trastuzumab-dkst for adjuvant treatment of early HER2-positive breast cancer in Brazilian patients. Data were collected using a case-report form. Results Of the 176 recruited, we present data from the first 59 patients (mean age 51.7 ± 12.9 years) who had completed treatment with trastuzumab-dkst. The mean time from diagnosis to the first adjuvant treatment with trastuzumab-dkst was 5.5 ± 2.7 months. Of the patients, 59% of patients achieved at least a 30-month follow-up. The 31.7-month invasive disease-free survival rate (IDFS) was 94.5% (95% CI 83.9–98.2%) and median IDFS was not achieved, since only three patients had invasive disease recurrence. The overall survival rate was 100% until the last assessment. The observed adverse events were similar to those presented by other studies using biosimilar or reference trastuzumab. Four serious adverse events (8.5%) were observed. A reduction in left ventricular ejection fraction of at least 10% was observed in 16.9% of participants. There was no treatment interruption, and three participants (5.1%) had their trastuzumab-dkst dose reduced. Conclusion Our study reinforces the existing pivotal data, underscoring the real-world efficacy and safety of biosimilar trastuzumab-dkst in the adjuvant treatment for early HER2-positive breast cancer. The preliminary long-term effectiveness and safety data we present further validate trastuzumab-dkst’s role as a cost-saving alternative in oncological care. These findings have important implications for improving patient access to crucial treatments and for the more efficient use of healthcare resources. ClinicalTrials.gov Registration NCT03892655.

1 January 2022 in Mastology
Verified
Journal Article
Open access
MCMarina de Paula Canal
Marina de Paula Canal
CRCaroline Gomes de Almeida Rocha
Caroline Gomes de Almeida Rocha
ABAlmir Bitencourt
Almir Bitencourt
MSMarina Sonagli
Marina Sonagli
COCynthia Aparecida Bueno de Toledo Osório
Cynthia Aparecida Bueno de Toledo Osório
FMFabiana Baroni Alves Makdissi
Fabiana Baroni Alves Makdissi
Introduction: The axillary lymph node status is one of the most important prognostic factors in breast cancer. For locally advanced tumors, neoadjuvant chemotherapy favors higher rates of breast lumpectomy and downstaging tumor burden of axilla. The aim of this study was to evaluate the use of a standardized image-guided protocol after neoadjuvant chemotherapy to enable sentinel node dissection in patients with axillary downstaging, avoiding axillary dissection. Methods: Retrospective cohort study of data collected from medical records of patients who underwent neoadjuvant chemotherapy in a single center, from January 2014 to December 2018. The protocol comprises the placement of a metal clip in positive axillary lymph node, in patients with up to two clinically abnormal lymph nodes presented on imaging. After neoadjuvant chemotherapy, and once a radiologic complete response was achieved, sentinel node dissection was performed using blue dye and radiotracer. Axillary dissection were avoided in patients whose clipped sentinel node were negative for metastasis and in patients with three identified and negative sentinel node dissection. Results: A total of 471 patients were analyzed for this study: 303 before and 165 after the implementation of the protocol; 3 cases were excluded. The rate of sentinel node dissection in clinical nodes positive patients was statistically higher in this group when compared to patients treated before the protocol implementation (22.8% vs. 40.8%; p=0.001). Patients with triple negative and HER2-positive tumors underwent sentinel node dissection more frequently when compared to luminal tumors (p=0.03). After multivariate analysis, the variables that were associated with a greater chance of performing sentinel node dissection were clinical staging, type of surgery performed and implementation of the axillary assessment protocol. Conclusions: The results showed that the use of an easily and accessible image-guided protocol can improve sentinel node dissection in selected patients, even if the lymph node was positive previously to neoadjuvant treatment.